Scarica l'app Stockscreener
54.07
5.17%
-2.95
Dopo l'orario di chiusura:
53.98
-0.09
-0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$57.02
Aprire:
$57.255
Volume 24 ore:
4.42M
Relative Volume:
0.61
Capitalizzazione di mercato:
$21.45B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-6.6375
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
-12.54%
1M Prestazione:
-10.51%
6M Prestazione:
+11.00%
1 anno Prestazione:
+58.98%
Intervallo 1D:
$53.85
$57.46
Intervallo di 1 settimana:
$53.85
$62.43
Portata 52W:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
54.07 | 22.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna: A Stock to Watch or a Risky Bet? - The Globe and Mail
Moderna stock may move 4.2% on July 31 earnings release By Investing.com - Investing.com Nigeria
Moderna Inc (MRNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Baillie Gifford (MRNA) discloses 18.2M Moderna shares in latest 13G/A - Stock Titan
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance Singapore
Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News - simplywall.st
First Trust Advisors LP Raises Stock Position in Moderna, Inc. $MRNA - MarketBeat
GC Biopharma Files for Phase 2 Trial of Korean-Made mRNA COVID-19 Vaccine, Aiming for August Start - finance.biggo.com
Moderna (MRNA) Projected to Post Earnings on Friday - MarketBeat
Earnings Preview: What To Expect From Moderna’s Report - Yahoo Finance
Moderna Inc (MRNA) Institutional Confidence - TradingKey
Biotech experts want FDA drug reviews based on science, not politics - marketscreener.com
Himension Capital Singapore PTE. LTD. Cuts Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Rabies Vaccine Candidate by Moderna Inc.mRNA approach in early trials - AD HOC NEWS
Bank of New York Mellon Corp Reduces Position in Moderna, Inc. $MRNA - MarketBeat
California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA - MarketBeat
Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near? - Yahoo! Finance Canada
Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift - Yahoo Finance UK
The mRESV by Moderna. An mRNA RSV vaccine candidate for older adults - Ad-hoc-news.de
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? - The Motley Fool
Moderna stock stabilizes as oncology pipeline and vaccine revenue reshape growth outlook - Ad-hoc-news.de
MRNA Maintained and Target Raised by Goldman Sachs -- Now $67.00 - GuruFocus
Moderna stock outlook: doubled YTD but Wall Street says the easy money is made - Investing.com
Moderna Inc. Stock Slides 3.8%, Underperforms Peers - webull.com
Moderna, Inc. $MRNA Stock Holdings Increased by Fifth Third Bancorp - MarketBeat
Moderna Hits CureVac With Countersuit In COVID Vax Fight - Law360
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback? - Yahoo Finance
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo! Finance Canada
Moderna, Inc.'s Stock Price Drops to $59.49, a Decline of 3.77%, Investors Eye Market Performance Closely - Smartkarma
Moderna says CureVac broke agreement by suing over COVID vaccine patents - Reuters
Moderna stock steadies as RSV and COVID vaccine revenues reshape outlook - AD HOC NEWS
Moderna counters CureVac patent lawsuit over Covid-19 vaccines By Investing.com - Investing.com Canada
Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating - marketscreener.com
Wolfe Research raises Moderna stock price target to $25 on updates - Investing.com
D.A. Davidson & CO. Decreases Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Encyclopedia Britannica
Moderna stock edges higher as Spikevax sales stabilize and pipeline spending stays elevated - ad-hoc-news.de
The mRNA-1345 RSV vaccine candidateModerna Inc. bets on older adults - Ad-hoc-news.de
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Moderna stock trades lower as COVID vaccine demand weighs on 2026 outlook - ad-hoc-news.de
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
MRNA Advances Cancer Pipeline With New Immunotherapy Study - Yahoo Finance
Moderna stock trades steadily as mRNA pipeline and COVID revenues shape outlook - ad-hoc-news.de
Fed. Circ. Asked Not To Shift Moderna Vax Patent Case To Gov't - Law360
Form 4 Moderna Inc For: 16 July By Investing.com - Investing.com Nigeria
Moderna, Inc.’s Stock Price Plummets to $63.15, Marking a Significant 7.51% Decline - Smartkarma
Moderna president Stephen Hoge sells $3.6m in stock - Investing.com
Moderna, Inc. (MRNA) president exercises options and sells 53,336 shares under 10b5-1 plan - Stock Titan
Lobbying Update: $290,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? - Stocktwits
The mRESVAI trial for RSV vaccine by Moderna Inc.early data underline a strategic bet on respirat - ad-hoc-news.de
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.46%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):